Arcus Biosciences, Inc. (RCUS) News
Track canonical SquawkNews coverage tagged to RCUS, Arcus Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 19 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Arcus Biosciences Price Target Maintained With a $43.00/Share by Wedbush
Ratings actions from Benzinga
NEWS | Sep 30, 2026, 12:35 PM UTC
L
Wedbush reiterates Outperform rating on Arcus Biosciences, $43 price target
Wedbush reiterated their Outperform rating on Arcus Biosciences's stock with a price target of $43.00.The price target implies an upside of 67.6% from the Sep 29 close of $25.65.Key takeaways from the analyst notePositiv
EQUITY | Sep 30, 2026, 12:24 PM UTC
L
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, toda
NEWS | Sep 24, 2026, 08:35 PM UTC
L
RCUS - Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
RCUS - Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
NEWS | Sep 22, 2026, 12:39 PM UTC
L
RCUS: Upcoming data for casdatifan may establish new benchmarks in kidney cancer treatment efficacy
Casdatifan is positioned for broad use in kidney cancer, with upcoming data expected to show strong efficacy and survival benefits across multiple treatment lines. The program is differentiated by robust performance in r
EQUITY | Sep 10, 2026, 03:10 PM UTC
L
RCUS: Upcoming data for casdatifan may establish new benchmarks in RCC treatment and commercial value
Casdatifan is positioned for broad use in clear cell RCC, with upcoming data expected to show strong efficacy and survival benefits across treatment lines. The program emphasizes real-world patient representation, innova
EQUITY | Sep 10, 2026, 02:43 PM UTC
L
RCUS - Arcus Biosciences Announces New Employment Inducement Grants
RCUS - Arcus Biosciences Announces New Employment Inducement Grants
EQUITY | Sep 09, 2026, 08:39 PM UTC
L
Arcus Biosciences announces new employment inducement grants
Arcus Biosciences said its Board compensation committee announced new employment inducement grants.
EQUITY | Sep 09, 2026, 08:35 PM UTC
L
RCUS: Major October data update for casdatifan aims to boost confidence in pivotal renal cancer trials
Significant data updates for casdatifan in renal cell carcinoma are expected in October, covering late-line, second-line, and frontline settings. Pivotal studies are progressing well, with first data readouts anticipated
EQUITY | Sep 09, 2026, 04:13 PM UTC
L
RCUS to see pivotal October data updates across casdatifan studies
RCUS says October will include significant updates across late-line, second-line and frontline casdatifan studies, with mature PFS and new OS data expected to differentiate from competitors.
EQUITY | Sep 09, 2026, 04:00 PM UTC
L
RCUS: Casdatifan and quemliclustat lead a robust pipeline with strong late-stage data and major market potential
A diverse late-stage oncology and immunology pipeline is highlighted by casdatifan, which shows superior efficacy and safety in RCC compared to current standards, and quemliclustat, which could transform 1L pancreatic ca
EQUITY | Sep 08, 2026, 08:52 PM UTC
L
RCUS price target raised to $40.00 from $35.00 by Truist
Truist Securities raised its price target on RCUS to $40.00 per share from $35.00, according to Benzinga.
EQUITY | Sep 08, 2026, 05:02 PM UTC
L
RCUS - Arcus Biosciences to Participate in Three Upcoming Investor Conferences
RCUS - Arcus Biosciences to Participate in Three Upcoming Investor Conferences
EQUITY | Aug 26, 2026, 08:13 PM UTC
L
Arcus Biosciences to take part in three investor conferences
Arcus Biosciences plans to participate in three upcoming investor conferences.
EQUITY | Aug 26, 2026, 08:05 PM UTC
L
RCUS - Arcus Biosciences Announces New Employment Inducement Grants
RCUS - Arcus Biosciences Announces New Employment Inducement Grants
EQUITY | Aug 11, 2026, 08:36 PM UTC
L
RCUS - Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
RCUS - Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
EQUITY | Aug 05, 2026, 08:18 PM UTC
L
RCUS PT raised from $32 to $45, maintains Buy @ HCW
RCUS PT raised from $32 to $45, maintains Buy @ HCW
EQUITY | Jul 20, 2026, 01:14 PM UTC
L
Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing
() -- Juan C. Jaen, President, on July 09, 2026, sold 68,569 shares in Arcus Biosciences (RCUS) for $2,031,919. Following the Form 4 filing with the SEC, Jaen has control over a total of 1,200,531 common shares of the co
GEOPOLITICS | Jul 13, 2026, 09:44 PM UTC
L
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply
This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology HIF-2a inhibition with casdatifan result
EQUITY | Jul 01, 2026, 03:02 PM UTC